Spironolactone

Spironolactone is a synthetic steroid that acts mainly as an antagonist of aldosterone, a hormone that governs the body's handling of salt and water ^[1]. By blocking aldosterone at its receptor it behaves as a potassium-sparing diuretic, promoting the loss of sodium and water while conserving potassium ^[1]. Because the same drug also blocks androgen receptors to a modest degree, it additionally functions as an antiandrogen, and this dual character explains its unusually broad range of uses ^[1].

The drug was discovered in 1957 and introduced at the end of that decade, initially as a diuretic and a treatment for the hormone disorder primary hyperaldosteronism ^[1]. Its role expanded dramatically after the landmark Randomized Aldactone Evaluation Study, known as RALES, which was stopped early in the late 1990s because adding spironolactone to standard therapy cut the risk of death in patients with severe heart failure by roughly thirty percent ^[1][2]. It is now a standard part of treatment for heart failure with reduced pumping function and is used as an add-on for blood pressure that resists other medicines ^[4].

Beyond the heart, spironolactone is used to relieve fluid buildup in conditions such as liver cirrhosis, and its antiandrogen activity has made it a mainstay in dermatology, where it treats acne, excess facial and body hair, and female-pattern hair loss, particularly in the context of polycystic ovary syndrome ^[1]. It is also widely used as an antiandrogen in feminizing hormone therapy for transfeminine people. It is taken by mouth as tablets or a liquid and is available generically worldwide.

Spironolactone is a prescription-only medicine. Its most important safety concern is a rise in blood potassium, which can become dangerous, so potassium levels and kidney function are usually monitored, and combining it with potassium supplements or certain other drugs increases the risk ^[3]. Its hormonal actions can cause breast tenderness or enlargement, including gynecomastia in men, and menstrual changes in women ^[1]. It is generally avoided in pregnancy because of theoretical effects on the developing fetus.

Spironolactone is prescription only. Its signature risk is high potassium, which can be dangerous, so potassium and kidney function need checking, especially alongside ACE inhibitors, ARBs, or potassium supplements. Because it touches sex hormones, men can get breast tenderness or enlargement, and women may notice menstrual changes; these are dose-related. Other effects include dizziness, low blood pressure, and stomach upset. It should be avoided in significant kidney impairment, existing hyperkalemia, and Addison's disease, and used carefully in pregnancy given its hormonal activity. Older warnings about tumors came from very high animal doses and are not considered relevant at human doses.

Hyperkalemia is the interaction that kills. Spironolactone blocks aldosterone at the distal nephron and holds potassium back, so it adds to ACE inhibitors, angiotensin receptor blockers, direct renin inhibitors, potassium supplements, other potassium sparing diuretics, calcineurin inhibitors, heparin, which suppresses aldosterone, and trimethoprim, which blocks the epithelial sodium channel much as amiloride does. NSAIDs belong on that list twice: they raise potassium and they blunt the diuretic and antihypertensive effect while worsening renal function.

Spironolactone reduces the clearance of digoxin and raises its concentration, and its metabolite canrenone cross reacts with several digoxin immunoassays, so a reported level can mislead as well as rise. Lithium clearance falls with any effective diuretic, spironolactone included, which pushes lithium toward toxic concentrations.

Added to other antihypertensives it deepens hypotension, and cholestyramine given alongside has produced hyperkalemic metabolic acidosis. The antiandrogen activity that makes spironolactone useful in acne also works against exogenous androgen therapy.

Checking a whole stack? Run it through interactions + stacks.

Spironolactone was developed by the American pharmaceutical company G.D. Searle & Company in the late 1950s, with the synthesis of the compound credited to chemists including John A. Cella and colleagues who were searching for a competitive antagonist of the salt-retaining hormone aldosterone. It was introduced clinically around 1959 to 1960 under the brand name Aldactone, becoming the first practical steroidal aldosterone antagonist.

For decades it was used chiefly as a potassium-sparing diuretic for fluid retention and hypertension, but its role expanded dramatically with the landmark Randomized Aldactone Evaluation Study (RALES), which in 1999 showed a substantial reduction in death among patients with severe heart failure. Its off-label use in dermatology and endocrinology, exploiting its antiandrogen activity, developed gradually over the same period. Today spironolactone is an inexpensive generic medicine and appears on the World Health Organization's list of essential medicines.

Spironolactone is regarded as one of the more versatile and enduring drugs in modern medicine, valued for combining a gentle potassium-sparing diuretic effect with genuine disease-modifying benefit in heart failure. Cardiologists respect it as a cornerstone of therapy for reduced-ejection-fraction heart failure and for resistant hypertension, where it often succeeds after other agents have failed.

In dermatology and women's health it has earned a devoted following as a well-tolerated oral option for persistent acne and hirsutism, and it plays an important supportive role in feminizing hormone therapy. Its main honest limitations are the need to monitor potassium and kidney function, and hormonal side effects such as breast tenderness that stem from its antiandrogen activity. That it remains a first-choice medicine more than sixty years after its introduction speaks to a remarkably favorable balance of benefit, safety, and affordability.